
News|Articles|May 1, 2002
Health systems/plans share common coverage vision for Clarinex, OTC Claritin
Last month the FDA's Nonprescription Drugs Advisory Committee unanimously supported loratadine's (Claritin, Schering-Plough) switch from prescription to over-the-counter status for treatment of chronic idiopathic urticaria, moving the drug one step closer to full OTC status (see significant event timeline in sidebar).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Researchers Urge Payers to Encourage, not Inhibit, Biosimilar Competition
2
The Rise of AI in Healthcare Shows Both Progress and Roadblocks
3
Challenges & Solutions behind post-acute care models with OneHome's Noel Gilliam
4
Izervay Continued to Show Benefit in Geographic Atrophy in Open-Label Study
5



















































